“Regarding Dr. Nguyen’s study, genomic classifiers are here. They are the future of our field for personalized prostate cancer therapy,” stated Sophia C. Kamran, MD, Assistant Professor of Radiation Oncology at Massachusetts General Hospital, speaking at a press conference where this abstract was discussed. Dr. Kamran was not involved in this study.
Sophia C. Kamran, MD
“This study demonstrates that we can use genomic classifiers at the point of care in patients with high-risk disease to understand who should have intensified therapy vs who should have deintensified therapy,” she continued.
“This is the first study to validate a genomic classifier using prospective randomized trials and biopsy samples from those trials. This is a first step. I encourage you to accrue patients to the NRG-GU009 study to move this effort along, so we can apply this to our patients in the clinic,” Dr. Kamran stated. “Genomic classifiers will be coming to the clinic at the point of care in due time,” she predicted.
DISCLOSURE: Dr. Kamran’s spouse is employed by Sanofi Genzyme.
A 22-genomic classifier (the Decipher score) was able to predict the course of disease in men with high-risk prostate cancer, according to a patient-level meta-analysis of three randomized clinical trials presented at the 2021 American Society for Radiation Oncology (ASTRO) Annual Meeting.1 Use of...